Overview

* Crinetics Q3 revenue missed analyst expectations

* Net loss for Q3 was $130.1 mln, compared to $76.8 mln last year

Outlook

* Company anticipates cash runway into 2029

Result Drivers

* R&D EXPENSES - Increase in R&D expenses due to personnel costs and clinical activities

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $143,000 $637,200

Revenue (12

Analysts

)

Q3 Net -$130.09

Income mln

Q3 Basic -$1.38

EPS

Q3 $142.73

Operatin mln

g

Expenses

Q3 -$142.59

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Crinetics Pharmaceuticals Inc ( CRNX ) is $83.00, about 48.8% above its November 5 closing price of $42.53

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)